via The Scientist Magazine
- No vaccines exist for human coronavirus infections. A new intranasal vaccine using an RNA virus for gene delivery protects against fatal MERS coronavirus infections in mice.
- The mice were genetically engineered to be susceptible to the MERS virus. All the mice that received the vaccine survived MERS, while the mice that had not received the vaccine did not.
- The researchers are now applying the same strategy to develop a vaccine for SARS-CoV-2, the virus that causes COVID-19, which has infected more than a million people worldwide.
No vaccines exist that protect people against infections by coronaviruses, including SARS-CoV-2, which causes COVID-19, or the ones that cause SARS and MERS. As COVID-19 continues to wreak havoc, many labs around the world have developed a laser-like focus on understanding the virus and finding the best strategy for stopping it.
This week in mBio, a journal of the American Society of Microbiology, a team of interdisciplinary researchers describes a promising vaccine candidate against the MERS virus. Since the MERS (Middle East Respiratory Syndrome) outbreak began in 2012, more than 850 people have died, and studies suggest the virus has a case fatality rate of more than 30%.
In the new paper, the researchers suggest that the approach they took for a MERS virus vaccine may also work against SARS-CoV-2. The vaccine’s delivery method is an RNA virus called parainfluenza virus 5 (PIV5), which is believed to cause a condition known as kennel cough in dogs but appears harmless to people. The researchers added an extra gene to the virus so that infected cells would produce the S, or spike, glycoprotein known to be involved in MERS infections.
“We know people have been exposed to PIV5, but it seems to be an innocuous virus in humans,” said pediatric pulmonologist and coronavirus expert Paul McCray, M.D., at the University of Iowa, in Iowa City, who co-led the new study with virologist Biao He, Ph.D., at the University of Georgia, in Athens. “PIV5 doesn’t seem to cause a cytopathic effect.” The MERS virus cannot replicate in mice, so to test the vaccine McCray developed a mouse model that mimics human infections. The mice had been genetically engineered to express DPP4, the protein used by the MERS virus as an entry point for human cells.
Lab tests showed that a single dose of the vaccine, given intranasally, effectively caused infected cells to produce the S protein, which in turn triggered immune responses against the protein in the animal host.
Four weeks after the mice received the vaccine, they were exposed to a strain of the MERS virus, adapted to the mice to cause a lethal infection. The MERS virus was also given to groups of mice that had received a different PIV5 vaccine—one without the genes for the S protein—or an intramuscular vaccine with inactivated MERS virus.
All the mice immunized with the modified PIV5 virus survived MERS virus infection. In contrast, all the mice immunized with the PIV5 without S died from the infection. The intramuscular vaccine of inactivated MERS virus only protected 25% of the mice from a lethal infection. The mice that received inactivated MERS virus showed above-average levels of eosinophils, white blood cells that indicate infection or inflammation. This connection raises a safety concern for inactivated MERS virus as a potential vaccine, said He. The study demonstrates that an intranasal, PIV5-based vaccine is effective against MERS in mice, said He, and should be investigated for its potential against other dangerous coronaviruses, including SARS-CoV-2.
“We’re quite interested in using viruses as gene delivery vehicles,” said McCray, who has also investigated similar strategies as a way to treat cystic fibrosis. Now, like colleagues around the world, McCray and He have both focused their research efforts on SARS-CoV-2, taking a similar tack to working with mouse models of infection and testing vaccines.
Finding an effective vaccine against the coronavirus that causes COVID-19 is a race against time, McCray said. “One hundred percent of the population is not going to be exposed to the virus the first time around, which means there will be more people to infect when it comes again,” he said. “We don’t know yet if people get lasting immunity from the SARS-CoV-2 infection, so it’s important to think about ways to protect the population.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Blocking coronavirus infections
- Revealed: 17 Existing Drugs, A Dietary Supplement That Can Block COVID-19 Infection In Cellson August 22, 2021 at 7:28 pm
A new study reveals many drugs that are already in use for other purposes to be effective in blocking or reducing COVID-19 infection in cells. This also includes a dietary supplement. TheHealthSite.co ...
- Covid-19: Australia reports record cases as police block Sydney proteston August 20, 2021 at 10:29 pm
Australian police patrolled the streets and blocked transport into the centre of Sydney on Saturday to prevent a planned anti-lockdown protest as the country reported a record high daily number of new ...
- Australia reports record COVID-19 cases as police block Sydney proteston August 20, 2021 at 7:52 pm
"at-above-post addthis_tool" data-url=" (Reuters) -Australian police patrolled the streets and blocked transport into the centre of Sydney on Saturday to prevent a planned anti-lockdown protest as the ...
- High Proportion of Delta Variant of Coronavirus Found in India’s Breakthrough Infections, Says INSACOG | 10 Points to Knowon August 20, 2021 at 4:43 am
According to INSACOG (the Indian SARS-CoV2 Genomics Consortium), 61 samples of Delta Plus variants have been detected in the country so far.
- This Compound Found In Breast Milk Shows Promise In Preventing COVID-19 Infectionon August 19, 2021 at 11:23 pm
A new study has found some existing drugs and one supplement to be effective against COVID-19. Could these help address the ongoing health crisis amid the delta surge?
Go deeper with Google Headlines on:
Blocking coronavirus infections
Go deeper with Bing News on:
- Fighting COVID With COVID: Driving the Disease to Extinction With a Defective Version of the SARS-CoV-2 Viruson August 22, 2021 at 4:38 am
Researchers design new COVID-19 therapy that uses a defective version of the SARS-CoV-2 virus to drive the disease-causing version to extinction. What if the COVID-19 virus could be used against ...
- Virus Mutation-Mapping Tool Could Yield Stronger COVID Boosters and Universal Vaccineson August 22, 2021 at 3:29 am
Researchers at CU Boulder have developed a platform that can quickly identify common mutations on the SARS-CoV-2 virus that allow it to escape antibodies and infect cells. Published recently in Cell ...
- PARTNER NEWS: Coats developing threads and engineered yarns powered by HeiQ Viroblock technologyon August 21, 2021 at 4:10 am
Coats, the world's leading industrial thread company, is partnering with HeiQ, a Swiss technology company, to incorporate HeiQ Viroblock technology into its engineered yarns. The agreement also gives ...
- The Latest: Georgia majors slam Gov. Kemp's order on viruson August 20, 2021 at 3:57 pm
ATLANTA — The mayors of some of Georgia’s largest cities are slamming Gov. Brian Kemp’s new order that aims to limit local efforts to curb the coronavirus pandemic. In an open letter on Friday, the ...
- Covid News: Three U.S. Senators Test Positive for Viruson August 19, 2021 at 9:57 am
Texas will drop its enforcement of the governor’s ban on mask mandates. Los Angeles city workers and Oregon’s educators and health workers must soon be vaccinated.